These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 25853815)

  • 21. The up-regulation of vascular endothelial growth factor in mutated Ha-ras HaCaT cell lines is reduced by a farnesyl transferase inhibitor.
    Charvat S; Duchesne M; Parvaz P; Chignol MC; Schmitt D; Serres M
    Anticancer Res; 1999; 19(1A):557-61. PubMed ID: 10226598
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nicotinamide phosphoribosyltransferase inhibition reduces intraplaque CXCL1 production and associated neutrophil infiltration in atherosclerotic mice.
    Nencioni A; da Silva RF; Fraga-Silva RA; Steffens S; Fabre M; Bauer I; Caffa I; Magnone M; Sociali G; Quercioli A; Pelli G; Lenglet S; Galan K; Burger F; Vázquez Calvo S; Bertolotto M; Bruzzone S; Ballestrero A; Patrone F; Dallegri F; Santos RA; Stergiopulos N; Mach F; Vuilleumier N; Montecucco F
    Thromb Haemost; 2014 Feb; 111(2):308-22. PubMed ID: 24196571
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of epigenetics in the endothelial cell shear stress response and atherosclerosis.
    Dunn J; Simmons R; Thabet S; Jo H
    Int J Biochem Cell Biol; 2015 Oct; 67():167-76. PubMed ID: 25979369
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraplaque neovascularization as a novel therapeutic target in advanced atherosclerosis.
    Van der Veken B; De Meyer GR; Martinet W
    Expert Opin Ther Targets; 2016 Oct; 20(10):1247-57. PubMed ID: 27148888
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice.
    Lu J; Xiang G; Liu M; Mei W; Xiang L; Dong J
    Atherosclerosis; 2015 Dec; 243(2):438-48. PubMed ID: 26520898
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ets2 determines the inflammatory state of endothelial cells in advanced atherosclerotic lesions.
    Cheng C; Tempel D; Den Dekker WK; Haasdijk R; Chrifi I; Bos FL; Wagtmans K; van de Kamp EH; Blonden L; Biessen EA; Moll F; Pasterkamp G; Serruys PW; Schulte-Merker S; Duckers HJ
    Circ Res; 2011 Aug; 109(4):382-95. PubMed ID: 21700929
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy with the farnesyl protein transferase inhibitor SCH66336 and SCH58500 (p53 adenovirus) in preclinical cancer models.
    Nielsen LL; Shi B; Hajian G; Yaremko B; Lipari P; Ferrari E; Gurnani M; Malkowski M; Chen J; Bishop WR; Liu M
    Cancer Res; 1999 Dec; 59(23):5896-901. PubMed ID: 10606231
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.
    Milojkovic Kerklaan B; Diéras V; Le Tourneau C; Mergui-Roelvink M; Huitema AD; Rosing H; Beijnen JH; Marreaud S; Govaerts AS; Piccart-Gebhart MJ; Schellens JH; Awada A
    Cancer Chemother Pharmacol; 2013 Jan; 71(1):53-62. PubMed ID: 23053259
    [TBL] [Abstract][Full Text] [Related]  

  • 31. BRCA1 is a novel target to improve endothelial dysfunction and retard atherosclerosis.
    Singh KK; Shukla PC; Quan A; Al-Omran M; Lovren F; Pan Y; Brezden-Masley C; Ingram AJ; Stanford WL; Teoh H; Verma S
    J Thorac Cardiovasc Surg; 2013 Oct; 146(4):949-960.e4. PubMed ID: 23415688
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.
    Wang E; Casciano CN; Clement RP; Johnson WW
    Cancer Res; 2001 Oct; 61(20):7525-9. PubMed ID: 11606389
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of SCH 59228, an orally bioavailable farnesyl protein transferase inhibitor, on the growth of oncogene-transformed fibroblasts and a human colon carcinoma xenograft in nude mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Li Z; Dell J; Lipari P; Malkowski M; Prioli N; Rossman RR; Korfmacher WA; Nomeir AA; Lin CC; Mallams AK; Doll RJ; Catino JJ; Girijavallabhan VM; Kirschmeier P; Bishop WR
    Cancer Chemother Pharmacol; 1999; 43(1):50-8. PubMed ID: 9923541
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Loss of collagen XVIII enhances neovascularization and vascular permeability in atherosclerosis.
    Moulton KS; Olsen BR; Sonn S; Fukai N; Zurakowski D; Zeng X
    Circulation; 2004 Sep; 110(10):1330-6. PubMed ID: 15313955
    [TBL] [Abstract][Full Text] [Related]  

  • 35. D609 inhibits progression of preexisting atheroma and promotes lesion stability in apolipoprotein e-/- mice: a role of phosphatidylcholine-specific phospholipase in atherosclerosis.
    Zhang L; Zhao J; Su L; Huang B; Wang L; Su H; Zhang Y; Zhang S; Miao J
    Arterioscler Thromb Vasc Biol; 2010 Mar; 30(3):411-8. PubMed ID: 20139365
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The farnesyl protein transferase inhibitor SCH66336 synergizes with taxanes in vitro and enhances their antitumor activity in vivo.
    Shi B; Yaremko B; Hajian G; Terracina G; Bishop WR; Liu M; Nielsen LL
    Cancer Chemother Pharmacol; 2000; 46(5):387-93. PubMed ID: 11127943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. THSD1 preserves vascular integrity and protects against intraplaque haemorrhaging in ApoE-/- mice.
    Haasdijk RA; Den Dekker WK; Cheng C; Tempel D; Szulcek R; Bos FL; Hermkens DM; Chrifi I; Brandt MM; Van Dijk C; Xu YJ; Van De Kamp EH; Blonden LA; Van Bezu J; Sluimer JC; Biessen EA; Van Nieuw Amerongen GP; Duckers HJ
    Cardiovasc Res; 2016 May; 110(1):129-39. PubMed ID: 26822228
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study.
    Ravoet C; Mineur P; Robin V; Debusscher L; Bosly A; André M; El Housni H; Soree A; Bron D; Martiat P
    Ann Hematol; 2008 Nov; 87(11):881-5. PubMed ID: 18641985
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.
    Smalley KS; Eisen TG
    Int J Cancer; 2003 Jun; 105(2):165-75. PubMed ID: 12673674
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death.
    Oumouna-Benachour K; Hans CP; Suzuki Y; Naura A; Datta R; Belmadani S; Fallon K; Woods C; Boulares AH
    Circulation; 2007 May; 115(18):2442-50. PubMed ID: 17438151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.